How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update);Conduite à tenir devant une réactivation EBV et un syndrome lymphoprolifératif à EBV, une réactivation ou infection à CMV et à HHV-6 après allogreffe de cellules souches hématopoïétiques: recommandations de la SFGM-TC (mises à jour)

Bulletin du Cancer

Volumn 104, Issue 12, 2017, Pages S181-S187

  Brissot, Eolia ^a,b,c   Alsuliman, Tamim ^d   Gruson, Bérengère ^e   Hermet, Eric ^f   Tirefort, Yordanka ^g   Yakoub Agha, Ibrahim ^d   Alain, Sophie ^h,i,j,k  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITÉ DE LILLE   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY OF LIMOGES   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j Centre national de référence des cytomégalovirus   (France)

^k UMR 1092   (France)

more..

Author keywords

Allogeneic stem cell transplantation; CMV; EBV; HHV 6

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL PRACTICE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; REVIEW; VIRUS REACTIVATION; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; EXANTHEMA SUBITUM; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MEDICAL SOCIETY; PHYSIOLOGY; PRACTICE GUIDELINE; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ROSEOLOVIRUS INFECTIONS; SOCIETIES, MEDICAL; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 85035066368     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2017.10.022     Document Type: Review

References (22)

1. Tipton, R., Yakoub-Agha, I., [How we harmonize HSCT clinical practices among the SFGM-TC centers]. Bull Cancer 103:11S (2016), S193–S197.
2. Bay, J.O., Peffault de Latour, R., Bruno, B., Coiteux, V., Guillaume, T., Hicheri, Y., et al. [Diagnosis and treatment of CMV and EBV reactivation as well as post-transplant lymphoproliferative disorders following allogeneic stem cell transplantation: an SFGM-TC report]. Pathol Biol (Paris) 61:4 (2013), 152–154.
3. Semenova, T., Lupo, J., Alain, S., Perrin-Confort, G., Grossi, L., Dimier, J., et al. Multicenter evaluation of whole-blood Epstein-Barr viral load standardization using the WHO international standard. J Clin Microbiol 54:7 (2016), 1746–1750.
4. Heslop, H.E., How I treat EBV lymphoproliferation. Blood 114:19 (2009), 4002–4008.
5. Styczynski, J., Tridello, G., Gil, L., Ljungman, P., Hoek, J., Iacobelli, S., et al. Impact of donor Epstein-Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European society for blood and marrow transplantation. J Clin Oncol 34:19 (2016), 2212–2220.
6. Dominietto, A., Tedone, E., Soracco, M., Bruno, B., Raiola, A.M., Van Lint, M.T., et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 47:1 (2012), 101–106.
7. Ljungman, P., Boeckh, M., Hirsch, H.H., Josephson, F., Lundgren, J., Nichols, G., et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64:1 (2017), 87–91.
8. Kotton, C.N., Kumar, D., Caliendo, A.M., Asberg, A., Chou, S., Danziger-Isakov, L., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:4 (2013), 333–360.
9. Emery, V., Zuckerman, M., Jackson, G., Aitken, C., Osman, H., Pagliuca, A., et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 162:1 (2013), 25–39.
10. Pietersma, F.L., van Dorp, S., Minnema, M.C., Kuball, J., Meijer, E., Schuurman, R., et al. Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis 52:7 (2011), e144–e148.
11. Thiele, T., Kruger, W., Zimmermann, K., Ittermann, T., Wessel, A., Steinmetz, I., et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 51:12 (2011), 2620–2626.
12. Anduze-Faris, B.M., Fillet, A.M., Gozlan, J., Lancar, R., Boukli, N., Gasnault, J., et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 14:5 (2000), 517–524.
13. Dulery, R., Salleron, J., Dewilde, A., Rossignol, J., Boyle, E.M., Gay, J., et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant 18:7 (2012), 1080–1089.
14. De Bolle, L., Naesens, L., De Clercq, E., Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 18:1 (2005), 217–245.
15. de Pagter, P.J., Schuurman, R., Meijer, E., van Baarle, D., Sanders, E.A., Boelens, J.J., Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J Clin Virol 43:4 (2008), 361–366.
16. Yamane, A., Mori, T., Suzuki, S., Mihara, A., Yamazaki, R., Aisa, Y., et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 13:1 (2007), 100–106.
17. Zerr, D.M., Human herpesvirus 6 (HHV-6) disease in the setting of transplantation. Curr Opin Infect Dis 25:4 (2012), 438–444.
18. Agut, H., Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol 52:3 (2011), 164–171.
19. Mori, Y., Miyamoto, T., Nagafuji, K., Kamezaki, K., Yamamoto, A., Saito, N., et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant 16:11 (2010), 1596–1602.
20. Ogata, M., Satou, T., Kadota, J., Saito, N., Yoshida, T., Okumura, H., et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis 57:5 (2013), 671–681.
21. Ljungman, P., de la Camara, R., Cordonnier, C., Einsele, H., Engelhard, D., Reusser, P., et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42:4 (2008), 227–240.
22. Pellett, P.E., Ablashi, D.V., Ambros, P.F., Agut, H., Caserta, M.T., Descamps, V., et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 22:3 (2012), 144–155.